Literature DB >> 15113876

Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus.

Aruna Panda1, Subbiah Elankumaran, Sateesh Krishnamurthy, Zhuhui Huang, Siba K Samal.   

Abstract

The hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) is an important determinant of its virulence. We investigated the role of each of the four functional N-linked glycosylation sites (G1 to G4) of the HN glycoprotein of NDV on its pathogenicity. The N-linked glycosylation sites G1 to G4 at residues 119, 341, 433, and 481, respectively, of a moderately pathogenic NDV strain Beaudette C (BC) were eliminated individually by site-directed mutagenesis on a full-length cDNA clone of BC. A double mutant (G12) was also created by eliminating the first and second glycosylation sites at residues 119 and 341, respectively. Infectious virus was recovered from each of the cDNA clones of the HN glycoprotein mutants, employing a reverse genetics technique. There was a greater delay in the replication of G4 and G12 mutant viruses than in the parental virus. Loss of glycosylation does not affect the receptor recognition by HN glycoprotein of NDV. The neuraminidase activity of G4 and G12 mutant viruses and the fusogenicity of the G4 mutant virus were significantly lower than those of the parental virus. The fusogenicity of the double mutant virus (G12) was significantly higher than that of the parental virus. Cell surface expression of the G4 virus HN was significantly lower than that of the parental virus. The antigenic reactivities of the mutants to a panel of monoclonal antibodies against the HN protein indicated that removal of glycosylation from the HN protein increased (G1, G3, and G12) or decreased (G2 and G4) the formation of antigenic sites, depending on their location. In standard tests to assess virulence in chickens, all of the glycosylation mutants were less virulent than the parental BC virus, but the G4 and G12 mutants were the least virulent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113876      PMCID: PMC400364          DOI: 10.1128/jvi.78.10.4965-4975.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Inhibition of fusion by neutralizing monoclonal antibodies to the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.

Authors:  R M Iorio; R L Glickman; J P Sheehan
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

2.  Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition.

Authors:  R M Iorio; R J Syddall; J P Sheehan; M A Bratt; R L Glickman; A M Riel
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

3.  Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: monoclonal antibodies to some sites prevent viral attachment.

Authors:  R M Iorio; R L Glickman; A M Riel; J P Sheehan; M A Bratt
Journal:  Virus Res       Date:  1989-07       Impact factor: 3.303

4.  N-linked glycosylation of rabies virus glycoprotein. Individual sequons differ in their glycosylation efficiencies and influence on cell surface expression.

Authors:  S H Shakin-Eshleman; A T Remaley; J R Eshleman; W H Wunner; S L Spitalnik
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

5.  Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene.

Authors:  T Sakaguchi; T Toyoda; B Gotoh; N M Inocencio; K Kuma; T Miyata; Y Nagai
Journal:  Virology       Date:  1989-04       Impact factor: 3.616

6.  Structure and function of a membrane anchor-less form of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus.

Authors:  A M Mirza; J P Sheehan; L W Hardy; R L Glickman; R M Iorio
Journal:  J Biol Chem       Date:  1993-10-05       Impact factor: 5.157

7.  RNA editing in Newcastle disease virus.

Authors:  M Steward; I B Vipond; N S Millar; P T Emmerson
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

8.  An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.

Authors:  N K Back; L Smit; J J De Jong; W Keulen; M Schutten; J Goudsmit; M Tersmette
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

9.  Role of N-linked glycans in antigenicity, processing, and cell surface expression of bovine herpesvirus 1 glycoprotein gIV.

Authors:  S K Tikoo; M D Parker; J V van den Hurk; J Kowalski; T J Zamb; L A Babiuk
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus.

Authors:  S Li; J Schulman; S Itamura; P Palese
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more
  26 in total

1.  Pathogenicity evaluation of different Newcastle disease virus chimeras in 4-week-old chickens.

Authors:  Leonardo Susta; Patti J Miller; Claudio L Afonso; Carlos Estevez; Qingzhong Yu; Jian Zhang; Corrie C Brown
Journal:  Trop Anim Health Prod       Date:  2010-07-08       Impact factor: 1.559

2.  Evaluation of the contributions of individual viral genes to newcastle disease virus virulence and pathogenesis.

Authors:  Anandan Paldurai; Shin-Hee Kim; Baibaswata Nayak; Sa Xiao; Heather Shive; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

3.  Site-specific glycosylation of the Newcastle disease virus haemagglutinin-neuraminidase.

Authors:  Cassandra L Pegg; Christine Hoogland; Jeffrey J Gorman
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

4.  Coordinate deletion of N-glycans from the heptad repeats of the fusion F protein of Newcastle disease virus yields a hyperfusogenic virus with increased replication, virulence, and immunogenicity.

Authors:  Sweety Samal; Sunil K Khattar; Sachin Kumar; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

5.  Complete genome sequence of a velogenic Newcastle disease virus isolated in Mexico.

Authors:  Angel E Absalón; Andrea Mariano-Matías; Alejandra Vásquez-Márquez; Andrés Morales-Garzón; Diana V Cortés-Espinosa; Roberto Ortega-García; Eduardo Lucio-Decanini
Journal:  Virus Genes       Date:  2012-07-21       Impact factor: 2.332

6.  Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.

Authors:  Ekaterina G Viktorova; Sunil K Khattar; Diana Kouiavskaia; Majid Laassri; Tatiana Zagorodnyaya; Eugenia Dragunsky; Siba Samal; Konstantin Chumakov; George A Belov
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

7.  Cloning and characterization of a sialidase from the filamentous fungus, Aspergillus fumigatus.

Authors:  Mark L Warwas; Juliana H F Yeung; Deepani Indurugalla; Arne O Mooers; Andrew J Bennet; Margo M Moore
Journal:  Glycoconj J       Date:  2010-07-23       Impact factor: 2.916

8.  Potential use of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed in Rachiplusia nu larvae as an immunogen for chickens.

Authors:  Silvina Chimeno Zoth; Evangelina Gómez; Juan Manuel Carballeda; Oscar Taboga; Elisa Carrillo; Analía Berinstein
Journal:  Clin Vaccine Immunol       Date:  2009-03-18

9.  Newcastle disease virus in Madagascar: identification of an original genotype possibly deriving from a died out ancestor of genotype IV.

Authors:  Olivier F Maminiaina; Patricia Gil; François-Xavier Briand; Emmanuel Albina; Djénéba Keita; Harentsoaniaina Rasamoelina Andriamanivo; Véronique Chevalier; Renaud Lancelot; Dominique Martinez; R Rakotondravao; Jean-Joseph Rajaonarison; M Koko; Abel A Andriantsimahavandy; Véronique Jestin; Renata Servan de Almeida
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

10.  Role of the cytoplasmic tail amino acid sequences of Newcastle disease virus hemagglutinin-neuraminidase protein in virion incorporation, cell fusion, and pathogenicity.

Authors:  Shin-Hee Kim; Yongqi Yan; Siba K Samal
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.